Clinical Trial Update: A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 tolerability study of STX107 in adults with Fragile X Syndrome has been suspended, providing a status update on the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• STX107

Snippet

Sponsor: Seaside Therapeutics, Inc. | Conditions: Fragile X Syndrome | Phase 2 | Status: SUSPENDED